Atrial fibrillation (AF) is an important and independent risk factor for stroke, particularly in elderly people. The efficacy of treatment with warfarin and aspirin in primary and secondary stroke prevention in AF has been demonstrated in randomized clinical trials. In a demographic study, we examined the prevalence of AF in patients registered with a general practice in the North East of England; 91 patients with known AF were identified, 69 with chronic AF and 22 with paroxysmal AF. The mean duration of the arrhythmia was 6.43 years and the prevalence of AF increased with age. There was a high prevalence of cerebrovascular disease in AF patients. The majority of AF patients were not receiving therapy with aspirin or warfarin as primary or secondary stroke prevention. If strategies for stroke prevention in AF are to be applied to the community, general practitioners will need to play a more active part.
Introduction
The importance of atrial fibrillation (AF) as a major independent risk factor for stroke in the elderly population is clearly established [1] . There is now evidence from large randomized clinical trials for the efficacy of warfarin or aspirin in both primary and secondary stroke prevention in non-valvular (nonrheumatic) AF [2] . However, many doctors are reluctant to prescribe anticoagulant or antiplatelet therapy for elderly patients because of concerns about haemorrhagic side-effects and drug compliance [3] . Studies of patients with AF discharged from hospital have shown that many do not receive antithrombotic therapy [4, 5] . The majority of patients with AF who are at risk of first or recurrent stroke are elderly and residing in the community. They are often frail individuals with significant co-morbidity who are unable to attend hospital outpatient clinics for monitoring of prothrombin time [6] . The decision to commence antithrombotic therapy in such individuals may therefore be perceived as having a significant impact upon general practice resources.
We undertook this study to determine current use of aspirin and warfarin in patients with AF in a general practice population in the North of England.
Methods
Gateshead, Tyne and Wear, is an urban area with high levels of social deprivation. A fundholding general practice in Central Gateshead was chosen for study. Anticoagulation services are provided through the Haematology Department of the local District General Hospital. The practice list size is 9162 patients, 1421 of whom are aged over 65 years. Lists of patients known to have AF were identified from computerized practice records using disease-specific and drug-history searches. The diagnosis of AF was verified from the individual patient records; this was a clinical diagnosis, where necessary confirmed by 12-lead ECG. Information was obtained on cardiovascular history, vascular risk factors and current use of antithrombotic therapy. Analysis of results was performed with the SPSS-X for Windows statistical package using x 2 or Mann-Whitney U tests as appropriate.
Results
Ninety-one cases of known AF were identified whose mean age was 75. 
Discussion
This study confirms that many individuals with AF are known to their general practitioners and are readily identifiable for the purposes of stroke prevention therapy. In addition there will be patients with undiagnosed AF or paroxysmal AF in this community. However, our prevalence figures are similar to those obtained in a previous community survey in the North of England [7] and therefore it is unlikely that many cases were missed by our ascertainment method.
As in studies of hospital inpatients [4, 5] , we have found that many patients in the community are not given antithrombotic therapy for stroke prevention in AF. It is possible that in a few cases, there were relative contraindications to treatment with aspirin or warfarin, for example poor compliance with drug therapy, which were known to the general practitioner but not documented in the practice records. However, it is likely that most AF patients in this sample were suitable candidates for antithrombotic therapy, at least with aspirin.
Anticoagulation for stroke prevention in AF is costeffective only if the rate of haemorrhagic complications is low [8] , which may not be the case with frail elderly patients. In the European Atrial Fibrillation Trial of secondary stroke prevention in a relatively elderly population (mean age 71 years), the optimal intensity of anticoagulation was identified as an International Normalized Ratio (INR) between 2.0 and 2.9, with only two major haemorrhagic events occurring per 100 person-years of treatment. Most major bleeding complications were seen with INR greater than 5.0 [9] . There is no doubt that older patients are more sensitive to the effects of warfarin and there is a reduction in dose requirement with age [10] . However, studies have shown that, with regular INR monitoring, haemorrhagic complications from warfarin therapy can be avoided in elderly outpatients [11] .
Aspirin is less effective than warfarin in preventing stroke in patients with AF. In the European Atrial Fibrillation Trial, aspirin prevented 40 vascular events annually (mainly recurrent strokes) per 1000 patients treated compared with a reduction of 90 events per 1000 patients with warfarin [12] . Aspirin has the advantage of being safer and easier to administer than warfarin. Nevertheless we found in our study that patients with no known contra-indication to aspirin were not being offered treatment. Education regarding the benefits of stroke prevention in AF is required in primary care.
The major determinant of more widespread use of anticoagulants in the community is the practicality of regular INR monitoring in an older population who may have difficulty attending local anticoagulation services at the local hospital or health centre. To encourage general practitioners in addressing 'Health of the Nation' targets there is a role for extending Government support for primary and secondary stroke prevention strategies.
